Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

13 Aug
Palliative Care Formulary August 2019 Update

This update contains 2 revised monographs

The following monographs have been fully revised: Adjuvant analgesics; Benzodiazepines and z-drugs

13 Aug
AHFS Drug Information logo
AHFS August 2019 Update

This update contains 4 new monographs and 26 revised monographs.

New monographs: Ropivacaine; Ketamine; Alpelisib; Brexanolone

Revised monographs: Nitazoxanide; Vaccinia Immune Globulin IV; Tapentadol; Fidaxomicin; Letermovir; Ozenoxacin; Burosumab-twza; Dehydrated Alcohol; Patisiran; Galcanezumab-gnlm; Gilteritinib; HYDROcodone; HYDROmorphone; Levorphanol; Codeine; Meperidine; oxyCODONE; Chloramphenicol; Flucytosine; Pentazocine; Levodopa/Carbidopa; Benzocaine; Butorphanol; Local Anesthetics, Parenteral, General Statement; Nicotine; traMADol

13 Aug
Stockleys Drug Interactions_logo
Stockley’s Drug Interactions August 2019 Update

Stockley’s Drug Interactions update with new and revised monographs.

This update contains 2 new monographs, and 57 existing monographs have been updated. The chapter on the calcium channel blockers has been completely re-validated and updated.

13 Aug
Stockley's Interactions Checker_logo
Stockley’s Interaction Checker August 2019 Update

New and updated interactions now available 

For August, 715 new interactions have been added, and 1224 existing interactions have been updated. 

13 Aug
British National Formulary for Children logo
BNFC August 2019 Update

This update contains 4 significant changes, 1 dose change and 1 new preparation.

Significant Changes:

  • Contraceptives, hormonal: updated guidance on combined hormonal contraceptives.
  • Crohn’s disease: updated guidance on management.
  • Flutiform® 50 microgram/ 5 microgram inhaler (fluticasone with formoterol): age range extension to include children aged 5 to 12 years for the prophylaxis of asthma.
  • Oral retinoid medicines (acitretin, isotretinoin, and tretinoin): revised and simplified pregnancy prevention educational materials for healthcare professionals and women [MHRA/CHM advice]. 

Dose Changes:

  • Epipen® preparations (adrenaline/epinephrine) [body-weight ranges for children’s dosing updated]

New Preparations: Gilenya® [fingolimod].

 

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 

13 Aug
British National Formulary logo
BNF August 2019 Update

This update contains 14 significant changes, 1 dose change and 6 new preparations. 

Significant Changes:

  • Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer [NICE guidance]. 
  • Contraceptives, hormonal: updated guidance on combined hormonal contraceptives. 
  • Crohn’s disease: updated guidance on management. 
  • Direct-acting oral anticoagulants (DOACs) (apixaban, dabigatran etexilate, edoxaban, and rivaroxaban): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome [MHRA/CHM advice]. 
  • Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes [NICE guidance]. 
  • Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib [NICE guidance]. 
  • Lenalidomide plus dexamethasone for previously untreated multiple myeloma [NICE guidance].
  • Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies [NICE guidance]. 
  • Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality [NICE guidance]. 
  • GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide (Victoza®), lixisenatide, and semaglutide): reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued [MHRA/CHM advice]. 
  • Ocrelizumab for treating primary progressive multiple sclerosis [NICE guidance]. 
  • Olaratumab (Lartruvo®): withdrawal of the EU marketing authorisation due to lack of efficacy [MHRA/CHM advice].  
  • Oral retinoid medicines (acitretin, alitretinoin, bexarotene, isotretinoin, and tretinoin): revised and simplified pregnancy prevention educational materials for healthcare professionals and women [MHRA/CHM advice]. 
  • Urinary incontinence and pelvic organ prolapse in women: updated guidance on management. 

Dose Changes:

  • Epipen® preparations (adrenaline/epinephrine) [body-weight ranges for children’s dosing updated].

New Preparations: Ajovy® [fremanezumab], Glyxambi® [empagliflozin with linagliptin], Brinavess® [vernakalant], Vizimpro® [dacomitinib], Betesil® [betamethasone], Blissel® [estriol].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

 

View more